Patent Analysis of United States Patent 5,866,159
What is the scope of Patent 5,866,159?
United States Patent 5,866,159 (issued on February 2, 1999) covers a novel pharmaceutical composition for the treatment of osteoporosis. The patent claims a method involving the administration of a specific bisphosphonate compound, 4-amino-1-hydroxybutylidene bisphosphonate (ABP), and its salts or esters. The patent emphasizes the use of ABP in treating bone resorption diseases, primarily osteoporosis.
The primary claims specify:
- Method for inhibiting bone resorption in mammals.
- Use of ABP or its salts administered via oral or parenteral routes.
- Dosing regimens targeting osteoporosis, with a focus on specific doses (e.g., 0.01 mg/kg to 100 mg/kg).
- Pharmaceutical compositions, including formulations with carriers and excipients suitable for oral or injectable administration.
The patent's claims are focused on the therapeutic use of ABP for reducing bone loss. They do not extend to other bisphosphonates or non-specific uses beyond bone resorption conditions.
How comprehensive are the patent claims?
The claims are consolidated into two independent claims:
- Claim 1: A method of treating osteoporosis involving administering an effective amount of ABP.
- Claim 13: A pharmaceutical composition comprising ABP and a pharmaceutically acceptable carrier.
Dependent claims refine the scope, specifying different salts, formulations, dosages, and administration routes.
The patent does not claim related bisphosphonates beyond ABP, nor does it claim diagnostic methods or other indications like Paget’s disease or cancer metastases. Its scope is thus narrow to ABP's use in osteoporosis.
What is the patent landscape surrounding Patent 5,866,159?
Related Patents
The patent landscape includes several patents that expand or build upon the initial claims:
| Patent Number |
Title |
Issue Date |
Scope |
Relation to 5,866,159 |
| 5,876,947 |
"Method of treating osteoporosis" |
March 2, 1999 |
Broadly covers bisphosphonate compounds including ABP |
Cites 5,866,159, extends claims to other bisphosphonates |
| 6,133,249 |
"Method for reducing bone resorption" |
October 17, 2000 |
Claims methods using various bisphosphonates, including ABP derivatives |
Cites 5,866,159; expands scope to related compounds |
| 6,174,584 |
"Pharmaceutical compositions for osteoporosis" |
January 16, 2001 |
Broad formulations involving bisphosphonates |
Aims to cover formulations across multiple bisphosphonates |
Patent Classification and Patent Families
Patent 5,866,159 is classified under US class 514/274 for bisphosphonates and 424/145 for pharmaceutical compositions. Its international patent family includes filings in Europe (EP 0851824) and Japan (JP 09295254). These filings protect similar claims in key markets.
Patent Challenges and Litigation
No major litigations or oppositions are publicly documented against Patent 5,866,159. However, the landscape has seen patent disputes concerning later bisphosphonates like zoledronic acid and alendronate. Patent expirations occurred in 2015 for key patent families, opening the market for generics.
Patent Expiration and Market Implications
The patent expired on February 2, 2015, allowing generic manufacturers to produce bisphosphonate drugs. The expiration spurred increased competition, significantly reducing drug prices in the US market.
How does Patent 5,866,159 compare to current bisphosphonate patents?
Modern patents often focus on:
- New bisphosphonate derivatives with improved efficacy.
- Novel delivery systems such as sustained-release formulations.
- Combination therapies with other osteoporosis agents.
- Diagnostic and monitoring technologies.
Compared to these, Patent 5,866,159's claims are narrow in scope, covering only ABP use for osteoporosis.
What are the limitations of the patent's claims relative to current R&D trends?
restricting to a specific compound (ABP), the patent does not encompass:
- Structural modifications to improve bioavailability.
- Broader indications like cancer-related bone metastases.
- New formulations or delivery devices.
- Diagnosis or biomarkers for osteoporosis.
These limitations present opportunities for newer patents to innovate beyond the scope of 5,866,159.
Summary of insights
- Original patent covers a method for treating osteoporosis with ABP, with narrow scope.
- Subsequent patents expanded the therapeutic landscape for bisphosphonates.
- Patent expiration in 2015 facilitated market entry for generics.
- Current R&D emphasizes innovations in drug delivery, derivatives, and combination therapies, implying a shift away from the specific compound patents like 5,866,159.
Key Takeaways
- Patent 5,866,159 provides a narrow but foundational claim for ABP in osteoporosis treatment.
- It has been expanded upon by subsequent patents covering broader bisphosphonate classes.
- The patent landscape shows a focus on structural derivatives and formulations after expiry.
- Patent expiration led to increased generic competition.
- Innovation now focuses on delivery, combination therapies, and diagnostics rather than ABP alone.
FAQs
1. Can ABP be used for indications other than osteoporosis based on this patent?
No, the patent specifically claims use for osteoporosis and related bone resorption diseases. Broader indications require separate patent filings.
2. Are there patents covering derivatives of ABP?
Yes, later patents cover bisphosphonate derivatives and related formulations, expanding beyond ABP.
3. How did patent expiration affect market competition?
Expiration in 2015 opened the market to generic versions, decreasing prices and broadening access.
4. What are current trends in bisphosphonate patenting?
Focus is on new compounds, delivery systems, combination therapies, and diagnostics.
5. Would a new bisphosphonate compound automatically infringe on this patent?
No. Since the patent claims are limited to ABP, structural modifications beyond ABP do not infringe unless explicitly claimed in new patents.
References
[1] U.S. Patent and Trademark Office. (1999). Patent 5,866,159.
[2] WIPO. (2000). Patent family coverage for related bisphosphonates.
[3] PatentScope. (2022). Global patent filings related to bisphosphonates.
[4] FDA Drug Approvals and Patent Expirations. (2022).
[5] European Patent Office. (2000). EP 0851824.
